• Publications
  • Influence
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCa2 mutation. Expand
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. Expand
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
  • P. Fong, T. Yap, +15 authors S. Kaye
  • Medicine
  • Journal of clinical oncology : official journal…
  • 20 May 2010
Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity, a significant association between the clinical benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups. Expand
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Abiraterone acetate has significant antitumor activity in post-docetaxel patients with castration-resistant prostate cancer (CRPC), and Randomized, phase III trials of abirater one acetate are underway to define the future role of this agent. Expand
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
CTC counts predict OS and provide independent prognostic information to time to disease progression to predict OS; CTC dynamics following therapy need to be evaluated as an intermediate end point of outcome in randomised phase III trials. Expand
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
In chemotherapy-naive patients with metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plusprednisone, however, no improvement was noted in the other primary endpoint, overall survival. Expand
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
Stable disease was observed at four cycles in more than half of the patients treated and a confirmed radiological partial response with a >50% decline in PSA in a patient with hormone refractory prostate cancer were observed. Expand
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Carlumab was well tolerated with evidence of transient free CCL2 suppression and preliminary antitumor activity and the recommended phase II dose was 15 mg/kg every 2 weeks. Expand
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
At the dose and schedule selected, romidepsin demonstrated minimal antitumor activity in chemonaive patients with CRPC, and further studies of improved HDACi, alone and in combination with other therapies, should nevertheless be investigated. Expand
5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent
Doses in the range of 1,200 mg m−2 have been selected for further studies because this dose produced no significant effect on heart rate–corrected cardiac QT interval, produced near maximum levels of 5-hydroxyindoleacetic acid, achieved DMXAA plasma concentrations within the preclinical therapeutic range, and was well tolerated. Expand